SARS-CoV-2 antibody response among COVID-19 patients is not affected by parasite co-infection

Study design, period, and setting

The study is part of the ongoing Profile-Cov study, a prospective observational cohort study in Ethiopia with rapid diagnostic profiling of SARS-CoV-2 in the context of persistent immune activation (Clinicaltrials.gov: NCT04473365). Consecutive patients with confirmed Real–Time polymerase chain reaction (RT-PCR) test results were enrolled. They were recruited from Mekelle University College of Health Sciences (Kuyha COVID-19 Isolation and Treatment Center), Mekelle City, Northern Ethiopia, prospectively between July 15 and October 28, 2020.

Individuals presenting to the Isolation and Treatment Center were screened for SARS-CoV-2 infection with a nasopharyngeal swab and an RT-PCR confirmed patients. Following the declaration by the WHO that COVID-19 has become a pandemic, the Ethiopian Ministry of Health implemented a mass screening of all travelers, people who had come in contact with COVID-19 patients, those from high-risk settings (e.g. healthcare workers), as well as those with symptoms and signs suggestive of SARS-CoV-2 infection [32]. All cases with a confirmed SARS-CoV-2 infection were admitted to dedicated COVID-19 Isolation and Treatment Centers. Patients were admitted irrespective of clinical severity status. Whenever patients progress to severe or critical COVID-19, they were admitted to the intensive care unit (ICU). None of the patients received SARS-CoV-2 vaccination as they were enrolled before the introduction of a vaccine to the country.

Data and specimen collection

Sociodemographic, clinical data, and laboratory data were collected using standardized Case Record Forms (CRFs) adapted from the International Severe Acute Respiratory and Emerging Infection Consortium’s (ISARIC) CRFs for emerging severe acute respiratory infections [33]. All data were then entered onto electronic medical records.

For analysis of anti-NP antibody kinetics, samples were drawn serially from 72 SARS-CoV-2 RT-PCR-confirmed patients. Overall, patients were followed for a median of 31 [interquartile range (IQR): 17-32] days, and ranging between 7 to 37 days. Whenever possible, samples were drawn every 3 days during follow-up. Thus, multiple samples were drawn per individual at a given time interval (0–3, 4–6, 7–9, 10–12, 13–15, 16–18, 19–21, 22–24, 25–27, 28–30, 31–33, 34–36, 37–39, and ≥ 40 days after onset of symptoms). Notably, only one sample per time interval was included from a single participant. Specimens were immediately transported to the Central Laboratory of the university hospital, and separated plasma was frozen at –80°C until further analysis.

Laboratory assays

SARS-CoV-2 infection was confirmed by RT-PCR on samples obtained from nasopharyngeal swabs, as described previously [32]. The antibody profile in this study was determined using the Roche Elecsys electrochemiluminescent immunoassay (ECLIA) that targets the nucleocapsid protein (NP). Testing, including the cut-off index (COI) for anti-NP total immunoglobulin (Ig) titer was done following the manufacturer’s instructions, as described previously [34]. Seroconversion was ascertained if a patient with a negative antibody test at the time of enrollment becomes positive with the assays tested during follow-up. For estimating the day of seroconversion, the day’s post-symptom onset was determined for symptomatic cases. For asymptomatic patients, we added 6 days (median time between symptom onset and date of positive PCR testing among symptomatic cases) to the PCR testing date. Fresh stool sample specimens were also obtained for examination for parasites and ova. The analysis included direct microscopic examination, modified Ritchie concentration method, and Kato-Katz method, as described previously [35].

Statistical Analysis

Baseline characteristics for continuous variables were expressed as the median with IQR, and for categorical variables as proportions. Categorical variables were compared using Fisher’s exact test or χ² test, and continuous variables were compared by Mann–Whitney U or Kruskal–Wallis tests as appropriate. The primary outcomes for this study were anti-NP total Ig positivity rate or titers above the COI value, according to sampling time (days after symptom onset). The positivity rate was presented as proportion and 95% confidence interval (CI) limits. Data were analyzed using STATA (Statistical package v. 14.0, StataCorp, Texas, USA).

Ethical considerations

Participants provided written informed consent to participate in the Profile-Cov study. The study protocol was reviewed and approved by the Health Research Ethics Review Committee (HRERC) of Mekelle University College of Health Sciences (#ERC 1769/2020). Written informed consent was obtained from all study participants. However, specimens used as controls from pre– pandemic period were specimens from biobank and individual study participant consent was not obtained. Nonetheless, all personal identifiers were–linked from the sources, and the HRERC has reviewed and approved it.

General characteristics

Detailed demographic and clinical characteristics of the cohort have been described previously in detail in our published articles [34, 35]. For this sub-study, 72 PCR-confirmed COVID-19 patients were enrolled and contributed a total of 589 samples [median of 9 (IQR: 5 – 11) paired samples per patient] collected serially over time. Of the 72 COVID-19 patients, 39 (54.2%) were co-infected with intestinal parasites while 33 (45.8%) had no parasitic co-infection. Details in sociodemographic characteristics and prevalence of parasite co-infection are summarized in Table 1. Frequent symptoms were fever, dyspnoea, cough, and headache. Except for dyspnoea which was significantly higher among those without parasites, clinical symptoms were similar in both groups. In addition, the groups did not differ by age, sex, comorbidities, or severity.

Longitudinal SARS-CoV-2 antibody response

The overall antibody NP total Ig response is summarized in Table 2. A total of 589 specimens derived at different time points were evaluated. The overall positivity rate for anti-SARS-CoV-2 total Ig was 68.8% (95% CI: 65.01-72.51); 70.4% (95% CI: 65.46-75.39) for those infected with parasites and 66.7% (95% CI: 60.91-72.42) for those not co-infected with parasites (p=0.328). Additionally, the positivity rate was 69.7% (95% CI: 62.61-76.78) for those infected with helminths and 68.4% (95% CI: 63.95-72.84) for those not co-infected with helminths (p=0.760). Whereas the anti-SARS-CoV-2 NP total Ig was 68.8% (95% CI: 65.01-72.51) among those infected with protozoa, it was 67.4% (95% CI: 62.62-72.13) among those without protozoa (p=0.333). Moreover, we did not observe differences in the anti-NP total Ig titers between those infected with parasites and those without parasite co-infection (Table 2).

The kinetics of the anti-NP total Ig response are shown in Figure 1. The seropositivity rate was low at the time of enrollment in the study. Overall the positivity rate for anti-NP total Ig was 11.1% in those co-infected with parasites and 14.3% in those without parasites (Figure 1A). Similar trends were observed among those with or without helminth (Figure 1B), or with or without protozoa (Figure 1C). However, during the first 15 days after the onset of symptoms, the positivity rate increased significantly reaching above 50% positivity rate, irrespective of parasite co-infection status. During the period 2-to 3 weeks after the onset of symptoms, the positivity rate of all the assays was increased, ranging between 67.3% and 81.3%. Between 3 and 6 weeks after the onset of symptoms, the positivity rate continued to increase for all the assays, ranging from 84.6% to 90.9%. Positive anti-NP total Ig titer was detectable (i.e. COI ≥ 1.0) as early as 7 to 12 days after onset of symptoms for all patients (Figure 1D–F). Because of the small sample size, we did not determine trends stratified by severity status.

• Download figure
• Open in new tab

Figure 1.

Anti-NP total Ig positivity rate (A-C) and titer levels (D-F) at different time points after onset of symptoms stratified by the parasite (A, D), helminth (B, E) and protozoa (C, F) co-infection status. The red dashed horizontal line (D-F) represents the cut-off value of the limit of detection of the anti-NP total Ig assay.

Seroconversion of SARS-CoV-2 antibodies

Patients who were antibody–negative at the time of enrollment in the study, but who became antibody–positive during follow–up were considered seroconverters. Overall, a total of 31 (41.9%) were seroconverted. A total of 256 sample pairs were evaluated. Seroconversion trends are shown in Figure 2. Patients started to seroconvert as early as 4 to 9 days after the onset of symptoms, reaching around 25%. The rate of seroconversion within the first 15 days after the onset of symptoms increased to 44.4%. During the same period, the rate of seroconversion for those with parasites was 47.1% (95% CI: 20.61-76.94), and for those without parasitic co-infection was 40.0% (95% CI: 3.06-76.94), and the difference was not statistically significant (p=0.722). In addition, the seroconversion rate increased further during 2-to 3 weeks after the onset of symptoms, ranging between 61.5% and 68.0%, respectively. The seroconversion rate continued to increase reaching 100% after ≥ 39 days of symptom onset in all groups (Figure 2A). Trends in anti-NP total Ig titers were also similar in patients irrespective of the presence of parasite co-infection or not (Figure 2B). Whereas the median seroconversion time for those with parasites was 13 (IQR: 7-21) days, it was 15 (IQR: 10-16) days for those without parasitic co-infection (p=927). Overall, there was no difference in seroconversion trend between those who were co-infected with parasites and those without parasites. Due to the small sample size, however, we did not do an analysis stratified by helminths and protozoa.

• Download figure
• Open in new tab

Figure 2.

Seroconversion rate (A) and titers levels (B) of anti-NP total Ig at different time points after onset of symptoms stratified by parasite co-infection status. The red dashed horizontal line (B) represents the cut-off value of the limit of detection of the anti-NP total Ig assay.